Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib

Basit Öğe Kaydı
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authoridBaysal, Mehmet/0000-0001-7681-4623
dc.authoridDemirci, Ufuk/0000-0001-6923-1470
dc.authoridUmit, Elif/0000-0001-5589-3000
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.contributor.authorGulsaran, Sedanur K.
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorDemirci, Ufuk
dc.contributor.authorBas, Volkan
dc.contributor.authorKirkizlar, Hakki O.
dc.contributor.authorUmit, Elif
dc.contributor.authorDemir, Ahmet M.
dc.date.accessioned2024-06-12T11:03:38Z
dc.date.available2024-06-12T11:03:38Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin's lymphomas. According to phase studies and real-world data, reported serious adverse effects included atrial fibrillation, diarrhea, and bleeding diathesis. However, heart failure was not reported to be a probable adverse effect linked with ibrutinib. Case report In this paper, we present a 66-year-old female chronic lymphocytic leukemia patient who developed significant and symptomatic left ventricular dysfunction at the 13th month of ibrutinib treatment. Management and outcome Following cessation of ibrutinib, ejection fraction and clinical findings of the left ventricular dysfunction alleviated. Discussion Although the use of ibrutinib is generally well tolerated, cardiac functions should be monitored occasionally in all patients.en_US
dc.identifier.doi10.1177/1078155219852146
dc.identifier.endpage480en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue2en_US
dc.identifier.pmid31142233en_US
dc.identifier.startpage478en_US
dc.identifier.urihttps://doi.org/10.1177/1078155219852146
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21737
dc.identifier.volume26en_US
dc.identifier.wosWOS:000513263200030en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIbrutiniben_US
dc.subjectCLLen_US
dc.subjectLeft Ventricular Dysfunctionen_US
dc.subjectCardiomyopathyen_US
dc.subjectAtrial-Fibrillationen_US
dc.subjectTyrosine-Kinaseen_US
dc.subjectCardiotoxicityen_US
dc.subjectExerciseen_US
dc.subjectTherapyen_US
dc.subjectRisken_US
dc.titleLate onset left ventricular dysfunction and cardiomyopathy induced with ibrutiniben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu